Fiche du document
- doi: 10.1038/s41586-018-0645-6
- issn: 0028-0836
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41586-018-0645-6
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30356218
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1476-4687
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7236863D48136
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Vitamin B3 Vitamin PP Nicotinic acid amide Niacinamide Speciation (Biology) Mouse House mice Mus musculus House mouse Primary metabolism Anabolism Metabolism, Primary Catabolism Wellness Personal health Family Family structure Families--Social aspects Families--Social conditions Family life Structure, Family Family relationships Relationships, Family Expressive behavior Soluble ferments Ferments Biocatalysts Aminopurine Biography--Health Biography--Ancestry Relations with family Biography--Descendants Biography--Family AncestryCiter ce document
E. Katsyuba et al., « De novo NAD+ synthesis enhances mitochondrial function and improves health. », Serveur académique Lausannois, ID : 10.1038/s41586-018-0645-6
Métriques
Partage / Export
Résumé
Nicotinamide adenine dinucleotide (NAD + ) is a co-substrate for several enzymes, including the sirtuin family of NAD + -dependent protein deacylases. Beneficial effects of increased NAD + levels and sirtuin activation on mitochondrial homeostasis, organismal metabolism and lifespan have been established across species. Here we show that α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), the enzyme that limits spontaneous cyclization of α-amino-β-carboxymuconate-ε-semialdehyde in the de novo NAD + synthesis pathway, controls cellular NAD + levels via an evolutionarily conserved mechanism in Caenorhabditis elegans and mouse. Genetic and pharmacological inhibition of ACMSD boosts de novo NAD + synthesis and sirtuin 1 activity, ultimately enhancing mitochondrial function. We also characterize two potent and selective inhibitors of ACMSD. Because expression of ACMSD is largely restricted to kidney and liver, these inhibitors may have therapeutic potential for protection of these tissues from injury. In summary, we identify ACMSD as a key modulator of cellular NAD + levels, sirtuin activity and mitochondrial homeostasis in kidney and liver.